Foxiga Korea Local Phase 4 Study - BEYOND

Study identifier:D1690L00067

ClinicalTrials.gov identifier:NCT02564926

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effects of Dapagliflozin Compared with Glimepiride on Body Composition in Patients with Type 2 Diabetes Inadequately Controlled with Metformin

Medical condition

Diabetes Mellitus, Type 2

Phase

Phase 4

Healthy volunteers

No

Study drug

Dapagliflozin, Glimepiride

Sex

All

Actual Enrollment

125

Study type

Interventional

Age

19 Years - 75 Years

Date

Study Start Date: 05 Jan 2016
Primary Completion Date: 15 Jan 2018
Study Completion Date: 15 Jan 2018

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria